RNS Number:0313D
Cross Shore Acquisition Corporation
30 August 2007


Cross Shore Acquisition Corporation

30 August 2007


                              Completion of Merger


Cross Shore Acquisition Corporation ("Cross Shore") announces today that,
following the waiver or satisfaction of all conditions to the merger agreement,
including the seeking of the requisite valuation opinion, it has now completed
its reverse takeover of ReSearch Pharmaceutical Services, Inc. (the
"Acquisition").

Admission to trading on AIM of Cross Shore's existing shares and warrants will
be cancelled and an application has been made for 40,699,958 shares and
1,971,847 warrants to be re-admitted to trading on AIM. The cancellation and
re-admission to trading of both the shares and warrants is expected to become
effective at 8.00 a.m. on 31 August 2007, as is the Company's change of name to
ReSearch Pharmaceutical Services, Inc. The Company's shares and warrants will
trade under the symbols RPSE and RPSW, respectively.

Until that time, trading in Cross Shore shares and warrants will remain
suspended.

Shareholders who have irrevocably elected to have their shares repurchased
should submit their share certificate(s) to Capita Registrars, The Registry, 34
Beckenham Road, Beckenham, Kent, BR3 4TU, UK, as soon as possible. Shareholders
should note that the repurchase value of $5.65 per share will only be paid on
delivery to Capita of the requisite share certificate(s). Any potential transfer
of a Cross Shore share which is the subject of a repurchase election will not be
registered by the Company. Any questions regarding delivery of share
certificates should be directed to Capita.



ENQUIRIES:

Cross Shore                             +1 843 597 4760
Dennis Smith

ReSearch Pharmaceutical Services        +1 215 540 0700
Dan Perlman

Arbuthnot Securities Limited            +44 207 012 2000
Nominated Adviser and UK Broker
James Steel / Guy Blakeney


Arbuthnot Securities Limited, which is authorised and regulated in the United
Kingdom by the Financial Services Authority, is acting as nominated adviser and
UK broker to the Company in connection with Re-admission. Its responsibilities
as the Company's nominated adviser under the AIM Rules are owed solely to the
London Stock Exchange and are not owed to the Company or to any Director or
Proposed Director or to any other person.

Arbuthnot Securities Limited is acting exclusively for the Company and for no
one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their clients or for providing advice in
relation to the contents of this announcement or the Re-admission. No
representation or warranty, express or implied, is made by Arbuthnot Securities
Limited as to the contents of this announcement. The information contained in
this announcement is not intended to inform or be relied upon by any subsequent
purchasers of Cross Shore Shares or Warrants (whether on or off exchange) and
accordingly no duty of care is accepted in relation to them.

The Directors and Proposed Directors of Cross Shore Acquisition Corporation
accept responsibility, individually and collectively, for the information
contained in this announcement and for compliance with the AIM Rules. To the
best of the knowledge and belief of the Directors and Proposed Directors, who
have taken all reasonable care to ensure that such is the case, the information
contained in this announcement is in accordance with the facts and does not omit
anything likely to affect the import of such information.


END





                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MERSDMFISSWSEIA
Cross Shore Acquisition (LSE:CSE)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Cross Shore Acquisition Charts.
Cross Shore Acquisition (LSE:CSE)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Cross Shore Acquisition Charts.